Fresenius Medical Care AG & Co. KGaA (FME) AI Stock Analysis

• Market Cap: €14.68B
• Dividend Yield: 2.87%
• Average Volume (3M): 572.86K
• Price to Earnings (P/E): 23.7
• Beta (1Y): 0.78
• Revenue Growth: 0.10%
• EPS Growth: 27.83%
• Country: DE
• Employees: 112,035
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Care Facilities
• EPS (TTM): 0.84
• Shares Outstanding: 293,413,450
• 10 Day Avg. Volume: 639,863
• 30 Day Avg. Volume: 572,855
• PEG Ratio: 1.60
• Price to Book (P/B): 1.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 7.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €48.64
• Price Target Upside: -3.72% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 13

• Rating: 68 Neutral
• Price Target: ―

Fresenius Medical Care presents a stable but modest investment opportunity. The company's financial performance is solid, with consistent margins and cash generation, but growth remains flat. Technical indicators point to a mixed outlook, with long-term potential but current bearish momentum. The valuation is slightly high, mitigated by a decent dividend yield, making it a reasonable option for investors seeking stability in the healthcare sector.

Positive Factors

Earnings

The company recorded better-than-expected results in Q1, leading to an increase in EPS estimates for 2025-26 and organic growth expectations.

Market Position

The company is the only one with FDA-approved technology for high-volume hemodiafiltration, positioning it advantageously in the market.

Technological Advancements

The introduction of new technology, such as the 5008X machine, is expected to support clinic utilization and improve patient care, which can enhance operational efficiency.

Negative Factors

Market Risks

Price cuts in China due to the new Value-Based Procurement are offsetting FME25 savings in Care Enablement.

Patient Coverage

Premium subsidies for ACA exchanges are likely to end in 2026, which could negatively impact the coverage for some patients and slightly affect EBIT.

Regulatory Challenges

There is continued caution on the dialysis market, which is seen as structurally challenged and at risk of reimbursement changes.

Fresenius Medical Care AG & Co. KGaA Business Overview & Revenue Model

Company Description

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

How the Company Makes Money

Fresenius Medical Care AG & Co. KGaA generates revenue primarily through its healthcare services and products. The company earns a significant portion of its income by providing dialysis services to patients, which includes both in-center hemodialysis treatments and home dialysis options. These services are often reimbursed through government health programs and private insurance. Additionally, FME produces and sells dialysis-related products, such as machines and consumables, to healthcare facilities and clinics globally. Strategic partnerships and agreements with healthcare providers and payers also play a crucial role in expanding its market reach and revenue generation. The company's integrated approach, combining services and products, allows it to capture value across the entire dialysis treatment chain.

Fresenius Medical Care AG & Co. KGaA Financial Statement Overview

Summary

Fresenius Medical Care demonstrates stable financial performance with consistent revenue and profit margins. The company maintains a balanced capital structure and strong cash generation capabilities, though growth is relatively flat, and leverage remains moderately high. The overall financial health is solid, but future improvements could focus on accelerating growth and enhancing returns.

Income Statement

Fresenius Medical Care experienced a slight revenue decline of approximately 0.6% from 2023 to 2024, following a similar trend from previous years. Despite this, the company maintained a strong gross profit margin of around 24.6% in 2024, reflecting efficient cost management. However, the net profit margin decreased slightly from 2.6% in 2023 to 2.8% in 2024. The EBIT margin improved slightly, indicating better operational profitability. Overall, the income statement reveals stable but not strong growth, with consistent margins indicating good operational efficiency.

Balance Sheet

The balance sheet shows a debt-to-equity ratio of approximately 0.75 in 2024, indicating a moderate level of leverage. The equity ratio of 43.4% suggests a balanced capital structure, though slightly lower than desirable for long-term stability. The return on equity (ROE) improved to 3.7% in 2024, reflecting better profitability. Overall, the balance sheet indicates adequate financial health with manageable leverage, but there is room for improvement in equity levels and returns.

Cash Flow

In 2024, operating cash flow decreased by 9.2% compared to 2023, yet free cash flow remained strong. The free cash flow to net income ratio was significant, indicating good cash generation relative to profits. However, the decrease in operating cash flow and free cash flow compared to previous years suggests potential challenges in maintaining cash generation levels. Overall, the cash flow statement shows a solid cash position but highlights the need for improved cash flow growth.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
19.49B	19.34B	19.45B	19.40B	17.62B	17.86B
	Gross Profit
4.77B	4.76B	4.93B	5.31B	5.08B	5.54B
	EBIT
1.41B	1.39B	1.37B	-258.36M	301.32M	529.00M
	EBITDA
3.06B	3.21B	2.93B	3.22B	3.42B	3.83B
	Net Income Common Stockholders
618.16M	537.91M	499.00M	673.40M	969.31M	1.16B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
846.38M	1.45B	1.54B	1.44B	1.62B	1.24B
	Total Assets
24.16B	33.57B	33.93B	35.75B	34.37B	31.69B
	Total Debt
7.72B	10.98B	12.05B	13.21B	13.32B	12.38B
	Net Debt
6.87B	9.83B	10.65B	11.94B	11.84B	11.30B
	Total Liabilities
13.25B	17.80B	19.10B	20.30B	20.39B	19.36B
	Stockholders Equity
9.90B	14.58B	13.62B	15.45B	13.98B	12.33B
Cash Flow		Free Cash Flow
1.98B	1.69B	1.94B	756.00M	806.00M	2.15B
	Operating Cash Flow
2.42B	2.39B	2.63B	2.17B	2.49B	4.23B
	Investing Cash Flow
-108.14M	-84.94M	-544.23M	-734.73M	-1.20B	-1.33B
	Financing Cash Flow
-976.16M	-2.57B	-1.86B	-1.62B	-1.02B	-2.66B

Fresenius Medical Care AG & Co. KGaA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 50.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FME, the sentiment is Positive. The current price of 50.52 is above the 20-day moving average (MA) of 50.35, above the 50-day MA of 46.00, and above the 200-day MA of 41.80, indicating a neutral trend. The MACD of 1.30 indicates Positive momentum. The RSI at 55.34 is Neutral, neither overbought nor oversold. The STOCH value of 17.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:FME.

Fresenius Medical Care AG & Co. KGaA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FME	68 Neutral	€14.68B	23.75	4.37%	2.87%	0.10%	27.83%
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%
0BFA		€37.47B	50.33	2.02%	5.40%	―	―
0P6S		€24.52B	―	-9.56%	0.44%	―	―
0O14		€50.02B	17.70	9.74%	1.92%	―	―
0NI1		€83.12B	106.16	21.45%	0.44%	―	―
0NIR		€12.80B	149.79	3.55%	0.36%	―	―